Compare SOLS & TECH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOLS | TECH |
|---|---|---|
| Founded | 2025 | 1976 |
| Country | United States | United States |
| Employees | 4400 | N/A |
| Industry | Aerospace | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.5B | 10.2B |
| IPO Year | N/A | 1995 |
| Metric | SOLS | TECH |
|---|---|---|
| Price | $71.93 | $51.40 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | $72.75 | ★ $73.09 |
| AVG Volume (30 Days) | ★ 3.2M | 2.1M |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | 0.40% | ★ 0.60% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.49 |
| Revenue | N/A | ★ $1,219,635,000.00 |
| Revenue This Year | $6.46 | $2.49 |
| Revenue Next Year | $5.00 | $6.40 |
| P/E Ratio | ★ $54.31 | $109.66 |
| Revenue Growth | N/A | ★ 5.23 |
| 52 Week Low | $40.43 | $46.02 |
| 52 Week High | $84.44 | $72.16 |
| Indicator | SOLS | TECH |
|---|---|---|
| Relative Strength Index (RSI) | 50.60 | 32.09 |
| Support Level | $47.09 | $48.93 |
| Resistance Level | $83.07 | $54.08 |
| Average True Range (ATR) | 3.23 | 2.46 |
| MACD | -1.22 | -0.38 |
| Stochastic Oscillator | 21.40 | 20.31 |
Solstice Advanced Materials is a diversified specialty chemicals company created in late 2025 after being spun off from Honeywell. It sells chemicals and materials to a wide range of end markets. Its largest product category is refrigerants used in heating, ventilation and air conditioning systems, and autos, where Solstice sells low global warming potential refrigerants. The company also sells materials used for building and construction, semiconductor production, healthcare packaging, and defense. Additionally, Solstice runs the only US uranium conversion business currently in operation.
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.